Your session is about to expire
← Back to Search
PD-1 Inhibitor
TATE + Pembrolizumab for Lung Cancer
Verified Trial
Phase 2
Recruiting
Research Sponsored by Teclison Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Have you been diagnosed with non-small cell lung cancer?
Has your lung cancer spread to your liver?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group
Approved for 10 Other Conditions
Summary
This trial is testing a new cancer treatment involving Trans-arterial Tirapazamine Embolization (a minimally-invasive procedure) and Pembrolizumab (a cancer immunotherapy drug). The trial is for patients with metastatic non-small cell lung cancer that has spread to the liver, and who have not responded to other treatments.
Who is the study for?
This trial is for adults with metastatic non-small cell lung cancer (NSCLC) who have already tried PD-1/PD-L1 inhibitors and chemotherapy. Patients whose disease has worsened after treatment are eligible to participate.
What is being tested?
The study tests whether combining Tirapazamine with embolization could enhance anti-tumor immunity and make Pembrolizumab effective in lung cancer patients who have failed prior immunotherapy.
What are the potential side effects?
Possible side effects include immune-related reactions due to Pembrolizumab like rash or colitis, liver issues from TATE, fatigue, skin changes, and increased risk of infections.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Overall Response Rate (ORR)
Secondary study objectives
Duration of Response
PFS
Response rate
+1 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
Trial Design
1Treatment groups
Experimental Treatment
Group I: NSCLCExperimental Treatment1 Intervention
Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy
Find a Location
Who is running the clinical trial?
Teclison Ltd.Lead Sponsor
3 Previous Clinical Trials
213 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
4,005 Previous Clinical Trials
5,185,328 Total Patients Enrolled
Ray LeeStudy DirectorTeclison Limited
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have not had major stomach or intestinal bleeding in the last 2 months.I am fully active or can carry out light work.My cancer has spread to the liver and does not have EGFR or AKT mutations.My cancer has spread to my brain.My organs are working well.My colorectal cancer has worsened after two treatments, or my lung cancer has worsened after chemotherapy and immunotherapy.I have had an organ transplant.It's been over 4 weeks since my last chemotherapy and I don't have side effects.The disease can be measured or seen on tests.Over half of my liver is affected by cancer.
Research Study Groups:
This trial has the following groups:- Group 1: NSCLC
Awards:
This trial has 2 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger